Vector System for Type 1 Diabetes Reversal via Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for type 1 diabetes mellitus are inadequate in effectively reversing hyperglycemia and suppressing the onset of the disease, as they often induce inflammatory responses and have limited efficacy in increasing tolerogenic dendritic cell and regulatory T cell populations.
Innovation Solution
A vector system comprising a first expression cassette encoding BCL2 associated X apoptosis regulator (BAX) and a hypermethylated second expression cassette encoding a secreted form of glutamic acid decarboxylase 65 (GAD65) is administered to induce a tolerogenic response, increasing tolerogenic dendritic cell populations and GAD-specific regulatory T cells in patients at risk of developing type 1 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-acting immunosuppressive therapeutics are used, then immune response is suppressed, but unwanted side effects occur and efficacy in increasing tolerogenic cells is limited
Solution Approach 1:
The patent segments the immune response modulation into specific targeted actions: inducing apoptotic cell death of autoreactive T cells while simultaneously expanding regulatory T cells and tolerogenic dendritic cells. This segmented approach allows suppression of autoimmune attack on beta cells without broad immunosuppression, thereby achieving disease suppression efficacy while avoiding the unwanted side effects of broad-acting immunosuppressants.
Solution Approach 2:
The patent introduces apoptotic cells as an intermediary mechanism. By inducing apoptosis of autoreactive T cells through targeted immunotherapy, the body naturally generates tolerogenic dendritic cells and regulatory T cells as intermediaries that mediate immune tolerance. This intermediary approach achieves reliable disease suppression without the harmful effects of direct broad immunosuppression.
2Productivity
If conventional immunotherapies are administered, then treatment is provided, but they fail to effectively reverse hyperglycemia and suppress diabetes onset
Solution Approach 1:
The patent fundamentally changes the therapeutic parameters by shifting from conventional immunosuppression to apoptosis-inducing immunotherapy. This parameter change involves using agents that trigger programmed cell death in autoreactive T cells while simultaneously stimulating the expansion of protective immune cell populations. This parameter transformation enables effective reversal of hyperglycemia and reliable suppression of diabetes onset, overcoming the limitations of conventional therapies.
Solution Approach 2:
The patent converts the harmful autoimmune attack into a beneficial therapeutic mechanism. By inducing controlled apoptosis of autoreactive T cells, the therapy transforms the destructive immune response into a protective mechanism that simultaneously eliminates pathogenic cells and stimulates the generation of tolerogenic dendritic cells and regulatory T cells. This conversion achieves both hyperglycemia reversal and diabetes onset suppression with high reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reverses hyperglycemia and suppresses the onset of type 1 diabetes by enhancing the numbers of tolerogenic dendritic cells and GAD-specific regulatory T cells, demonstrating significant efficacy in preclinical models by delaying or preventing diabetes onset.
Implementation Method 1
A promising class of immunotherapies utilize the natural cell death process, apoptosis
Implementation Method 2
a hypermethylated second expression cassette encoding a secreted form of glutamic acid decarboxylase 65
Data Source
AI summary
Methods of reversing hyperglycemia and suppressing diabetes onset in a patient at risk of developing type 1 diabetes are provided. In particular, a vector system comprising a first expression cassette encoding BCL2 associated X apoptosis regulator (BAX) and a hypermethylated second expression cassette encoding a secreted glutamic acid decarboxylase 65 (sGAD55) are administered to the patient to induce a tolerogenic response.